(19)
(11) EP 1 161 412 A1

(12)

(43) Date of publication:
12.12.2001 Bulletin 2001/50

(21) Application number: 00916297.5

(22) Date of filing: 13.03.2000
(51) International Patent Classification (IPC)7C07C 233/66, C07C 233/65, C07C 235/38, C07K 14/705, A61P 5/00, C07D 221/14
(86) International application number:
PCT/US0006/537
(87) International publication number:
WO 0055/118 (21.09.2000 Gazette 2000/38)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 16.03.1999 US 124635 P

(71) Applicant: GLAXO GROUP LIMITED
Greenford, Middlesex UB6 ONN (GB)

(72) Inventors:
  • BLANCHARD, Steven Gerard,Glaxo Wellcome Inc.
    Research Triangle Park, NC 27709 (US)
  • COBB, Jeffery Edmund,Glaxo Wellcome Inc.
    Research Triangle Park, NC 27709 (US)
  • COLLINS, Jon Loren,Glaxo Wellcome Inc.
    Research Triangle Park, NC 27709 (US)
  • WILLSON, Timothy Mark,Glaxo Wellcome Inc.
    Research Triangle Park, NC 27709 (US)

(74) Representative: Learoyd, Stephanie Anne et al
GlaxoSmithKlineCorporate Intellectual PropertyTwo New Horizons Court
Brentford, Middlesex TW8 9EP
Brentford, Middlesex TW8 9EP (GB)

   


(54) NUCLEAR RECEPTOR ARYLATING COMPOUNDS